Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Harvard Bioscience (HBIO) FCF Margin (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed FCF Margin for 16 consecutive years, with 2.3% as the latest value for Q4 2025.

  • Quarterly FCF Margin fell 810.0% to 2.3% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 6.32% through Dec 2025, up 760.0% year-over-year, with the annual reading at 6.32% for FY2025, 760.0% up from the prior year.
  • FCF Margin for Q4 2025 was 2.3% at Harvard Bioscience, down from 4.26% in the prior quarter.
  • The five-year high for FCF Margin was 16.34% in Q3 2023, with the low at 8.54% in Q1 2022.
  • Average FCF Margin over 5 years is 3.2%, with a median of 3.19% recorded in 2021.
  • The sharpest move saw FCF Margin plummeted -2418bps in 2024, then skyrocketed 2024bps in 2025.
  • Over 5 years, FCF Margin stood at 0.73% in 2021, then surged by 1279bps to 8.6% in 2022, then surged by 43bps to 12.34% in 2023, then tumbled by -53bps to 5.8% in 2024, then crashed by -140bps to 2.3% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 2.3%, 4.26%, and 13.04% for Q4 2025, Q3 2025, and Q2 2025 respectively.